Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Non-Current Deferred Tax Liability (2018 - 2024)

BioNexus Gene Lab's Non-Current Deferred Tax Liability history spans 7 years, with the latest figure at $13646.0 for Q3 2024.

  • Quarterly results put Non-Current Deferred Tax Liability at $13646.0 for Q3 2024, down 52.75% from a year ago — trailing twelve months through Sep 2024 was $13646.0 (down 52.75% YoY), and the annual figure for FY2023 was $12255.0, down 60.3%.
  • Non-Current Deferred Tax Liability for Q3 2024 was $13646.0 at BioNexus Gene Lab, up from $11918.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $30866.0 in Q4 2022 to a low of $1796.0 in Q3 2021.
  • The 5-year median for Non-Current Deferred Tax Liability is $19593.5 (2022), against an average of $17840.3.
  • The sharpest move saw Non-Current Deferred Tax Liability surged 1452.12% in 2022, then plummeted 61.16% in 2024.
  • Year by year, Non-Current Deferred Tax Liability stood at $1872.0 in 2020, then skyrocketed by 1417.95% to $28416.0 in 2021, then grew by 8.62% to $30866.0 in 2022, then tumbled by 60.3% to $12255.0 in 2023, then increased by 11.35% to $13646.0 in 2024.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $13646.0, $11918.0, and $11916.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.